Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study

Cover Page

Cite item

Full Text

Abstract

Background. Novel agents – immune checkpoint inhibitors – fundamentally changed the prognosis for life in patients with metastatic and/or inoperable melanoma. The development, studies, and approval of a new original PD1 inhibitor in Russia in 2020 prompted the professional community to conduct a prospective observational study in the Russian Federation to assess the real-world efficacy and safety of prolgolimab, as real-world patients differ from the refined population in clinical trials.

Aim. To evaluate the real-world efficacy and safety of prolgolimab in patients with metastatic and/or inoperable melanoma.

Materials and methods. From October 2020 to October 2022, the study enrolled 700 patients with metastatic and/or inoperable melanoma receiving prolgolimab in real clinical settings in oncological institutions of various levels in the Russian Federation. The main inclusion criteria were: pathology-confirmed diagnosis of melanoma, metastatic and/or inoperable type, use of prolgolimab outside of clinical trials, and signed informed consent by the patient. Objective response rate (ORR) was considered the main criterion for evaluating the efficacy of therapy, and the safety criterion was the incidence of grade 3–4 adverse events. Statistical analysis was performed using the SPSS 20.0 software package.

Results. The ORR for patients with skin melanoma treated with prolgolimab in the first line therapy (n= 207/337) was 48.3% (n=100), the disease stabilization was reported in 30.4% (n=63), and progression in 21.3% (n=44) of patients. There were no significant differences in response to therapy between patients with/without BRAF mutation, although ORR was higher in patients with BRAF mutation: the ORR for patients with BRAF mutation was 57.9% (n=33), and for BRAF non-mutated patients, 44.4% (n=52; p=0.222). At a median follow-up of 5 months, the median PFS was 10 months (95% confidence interval 7.35–12.64). The incidence of grade 3–4 treatment-related adverse events according to CTCAE 5.0 was 2% (n=12), and 12% (n=82) for grade 1–2 adverse events.

Conclusion. The results confirm the high efficacy and satisfactory tolerability of prolgolimab in patients with metastatic and/or inoperable melanoma in real-world settings. There were no significant differences in ORR between patients with or without BRAF mutation.

About the authors

Kristina V. Orlova

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: krisman03@gmail.com
ORCID iD: 0000-0002-0442-5917

Cand. Sci. (Med.)

Russian Federation, Moscow

Mikhail Yu. Fedyanin

Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka“; Pirogov National Medical and Surgical Center

Email: krisman03@gmail.com
ORCID iD: 0000-0001-5615-7806

D. Sci. (Med.)

Russian Federation, Moscow; Moscow; Moscow

Konstantin E. Simanenkov

Lipetsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Lipetsk

Aleksandr S. Dergunov

Tver Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tver

Petr R. Goldshmidt

Rostov-on-Don Oncological Dispensary

Email: krisman03@gmail.com

Deputy Chief Doctor

Russian Federation, Rostov-on-Don

Aleksandra F. Saydullaeva

Tver Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tver

Dary V. Bogacheva

Voronezh Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Voronezh

Marina A. Yavorskaya

Sochi Oncological Dispensary №2

Email: krisman03@gmail.com

Deputy Chief Doctor

Russian Federation, Sochi

Artur Z. Azanov

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Kemerovo

Alexander A. Fedenko

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4927-5585

D. Sci. (Med.)

Russian Federation, Moscow

Larisa V. Bolotina

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4879-2687

D. Sci. (Med.)

Russian Federation, Moscow

Tatyana I. Deshkina

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Moscow

Kseniya G. Babina

Volgograd Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Volgograd

Ekaterina A. Kuzevanova

Saratov Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Saratov

Liudmila G. Zhukova

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4848-6938

D. Sci. (Med.), Corr. Memb. RAS

Russian Federation, Moscow

Polina S. Feoktistova

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0002-0340-7119

Cand. Sci. (Med.)

Russian Federation, Moscow

Natalya I. Polshina

Loginov Moscow Clinical Scientific Center

Email: krisman03@gmail.com
ORCID iD: 0000-0001-5417-0425

Oncologist

Russian Federation, Moscow

Ekaterina V. Peganova

Yaroslavl Clinical Oncology Hospital

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yaroslavl

Valentina E. Shikina

Vladimirsky Moscow Regional Research Clinical Institute

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Moscow

Maksim M. Sobolev

City Clinical Oncology Hospital №1

Email: krisman03@gmail.com

Chemotherapist

Russian Federation, Moscow

Oleg V. Mironov

Tambov Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tambov

Vera A. Vaschenko

Kostroma Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kostroma

Mariya M. Ershova

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yekaterinburg

Agniya O. Mezhueva

Moscow Multidisciplinary Clinical Center “Kommunarka“

Email: krisman03@gmail.com

Department Head

Russian Federation, Moscow

Svetlana A. Orlova

Cheboksary Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Cheboksary

Denis A. Tantsyrev

Altai Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Barnaul

Darya K. Taskina

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: krisman03@gmail.com

Oncologist

Russian Federation, Chelyabinsk

Antonina A. Teterich

Belgorod Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Belgorod

Elena V. Karabina

Tula Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Tula

Yuliya V. Kostalanova

Samara Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Samara

Marina V. Bogacheva

Vologda Regional Clinical Hospital №2

Email: krisman03@gmail.com

Oncologist

Russian Federation, Vologda

Natalia V. Zhukova

Saint Petersburg State University; Saint Petersburg City Clinical Oncology Dispensary

Email: krisman03@gmail.com
ORCID iD: 0000-0002-0619-2205

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg

Rashida V. Orlova

Saint Petersburg City Clinical Oncology Dispensary

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4447-9458

D. Sci. (Med.), Prof.

Russian Federation, Saint Petersburg

Maksim V. Zinkevich

Leningrad Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Aleksandr I. Kazmin

Voronezh Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Voronezh

Mikhail V. Volkonskiy

Moscow City Oncological Hospital №62

Email: krisman03@gmail.com
ORCID iD: 0000-0003-4060-5015

Head of the Day Hospital

Russian Federation, Moscow

Liya M. Voronkova

Vladikavkaz Republican Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Vladikavkaz

Anastasiya S. Karpova

Trans-Baikal Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Chita

Mikhail L. Maleyko

Shakhty Oncological Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Shakhty

Mariya N. Gorshenina

Yoshkar-Ola Republican Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Yoshkar-Ola

Elena I. Kryuchkova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Smolensk

Fedor V. Moiseenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology)

Email: krisman03@gmail.com
ORCID iD: 0000-0003-2544-9042

D. Sci. (Med.)

Russian Federation, Saint Petersburg

Yuliya I. Murzina

Birobidzhan Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Birobidzhan

Shamil I. Musin

Ufa Republican Clinical Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Ufa

Andrey N. Ogloblin

Oryol Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Oryol

Mariya S. Perminova

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kemerovo

Regina A. Dumbrava

Primorsky Regional Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Vladivostok

Sergey A. Emelyanov

Primushko Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Izhevsk

Svetlana A. Protsenko

Petrov National Medical Research Center of Oncology

Email: krisman03@gmail.com

Department Head

Russian Federation, Saint Petersburg

Alexander V. Sultanbaev

Ufa Republican Clinical Oncology Center

Email: krisman03@gmail.com
ORCID iD: 0000-0003-0996-5995

Cand. Sci. (Med.)

Russian Federation, Ufa

Anna V. Tarasova

Samara Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Samara

Elena B. Shakhnovich

Korolyov City Hospital

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Korolyov

Marina V. Demchenkova

Irkutsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Irkutsk

Yuliya A. Lozovskaya

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Khedi S. Musaeva

Oncology Center “AiMed”

Email: krisman03@gmail.com

Department Head

Russian Federation, Grozny

Elena M. Pavlova

Vologda Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Vologda

Roman A. Skotnikov

Tula Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tula

Vera V. Chernova

Ryazan Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ryazan

Angelina S. Chichkanova

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Nizhny Novgorod

Adina M. Akhmatova

Nalchik Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Nalchik

Marina A. Zafirova

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of Chemotherapy Service

Russian Federation, Yekaterinburg

Andrey A. Mischenko

Primorsky Regional Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Vladivostok

Elena N. Ovsienko

Primushko Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Izhevsk

Viktoriya A. Petrukhnenko

Komsomolsk-on-Amur Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Komsomolsk-on-Amur

Oksana A. Syusyukaylova

Ashkhamaf Adygei Republican Clinical Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Maykop

Yana A. Tyugina

Ivanovo Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ivanovo

Elena A. Shumilkina

Cheboksary Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Cheboksary

Daniil L. Stroyakovskiy

Moscow City Oncological Hospital №62

Email: krisman03@gmail.com
ORCID iD: 0000-0003-1973-1092

Cand. Sci. (Med.)

Russian Federation, Moscow

Aleksandr N. Yurchenkov

Moscow City Oncological Hospital №62

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Moscow

Pavel L. Baldin

Naberezhnye Chelny Oncological Dispensary – branch of the Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Naberezhnye Chelny

Anastasiya S. Belova

Novgorod Regional Clinical Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Veliky Novgorod

Olga V. Diduk

Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Krasnoyarsk

Elena A. Konovalova

Murmansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Murmansk

Lyudmila N. Lebedeva

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Arkhangelsk

Yaroslav A. Li

Clinic Lyadov

Email: krisman03@gmail.com

Oncologist

Russian Federation, Khimki

Viktoriya V. Mashtapa

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Yana A. Mironenkova

Vologda Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Vologda

Kristina V. Narovenkova

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Olga A. Pavlikova

Yoshkar-Ola Republican Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yoshkar-Ola

Elvira L. Parsadanova

Sakhalin Regional Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Yuzhno-Sakhalinsk

Irina S. Pimonova

Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Obninsk

Anna A. Ruzhnikova

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Arkhangelsk

Irina D. Sivunova

Kamchatka Regional Oncology Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Petropavlovsk-Kamchatsky

Ekaterina P. Soloveva

Arkhangelsk Clinical Oncology Dispensary

Email: krisman03@gmail.com

Cand. Sci. (Med.)

Russian Federation, Arkhangelsk

Maksim I. Sosnin

Krasnogorsk City Hospital №1

Email: krisman03@gmail.com

Oncologist

Russian Federation, Krasnogorsk

Toita Kh. Temirsultanova

Oncology Center “AiMed”

Email: krisman03@gmail.com

Department Head

Russian Federation, Grozny

Makhabbat Zh. Tyulegenova

Orenburg Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Orenburg

Aleksandra V. Khodkevich

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Nadezhda R. Shakurova

Tomsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tomsk

Sureya N. Efendieva

Makhachkala Republican Cancer Center

Email: krisman03@gmail.com

Deputy Chief Doctor

Russian Federation, Makhachkala

Karine L. Avagimyan

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Ekaterina P. Anokhina

Ulyanovsk Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ulyanovsk

Mariya I. Antoshkina

Saransk Republican Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Saransk

Stanislav M. Borzyanitsa

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Kemerovo

Samir K. Dzhentemirov

Stavropol Regional Clinical Oncology Center

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Stavropol

Marina V. Dmitrochenko

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Alla V. Zheleznyak

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Nizhny Novgorod

Yuliya V. Komoza

Bryansk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Bryansk

Aleksandr S. Kopanev

Kirov Center of Oncology and Medical Radiology

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kirov

Tatyana I. Kornienko

Tambov Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Tambov

Margarita A. Krasilnikova

Rappoport Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Head of the Day Hospital

Russian Federation, Kemerovo

Darya A. Lukhmanova

Ulyanovsk Regional Clinical Oncology Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Ulyanovsk

Natalya S. Mazur

Sverdlovsk Regional Oncological Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Yekaterinburg

Polina M. Markina

Nizhny Novgorod Regional Clinical Oncology Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Nizhny Novgorod

Zhargal S. Mitapov

Buryat Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Ulan-Ude

Svetlana N. Osodoeva

Buryat Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Ulan-Ude

Irina A. Prokopenko

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Department Head

Russian Federation, Kursk

Irina M. Radyukova

Omsk Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Omsk

Madina S. Ramazanova

Kirov Center of Oncology and Medical Radiology

Email: krisman03@gmail.com

Department Head

Russian Federation, Kirov

Alfiya R. Safarova

Almetyevsk branch of the Republican Clinical Oncological Dispensary

Email: krisman03@gmail.com

Сhemotherapist

Russian Federation, Almetyevsk

Mariya A. Safronova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Khalimat M. Khabrieva

Republican Oncological Dispensary of the Republic of Ingushetia

Email: krisman03@gmail.com

Oncologist

Russian Federation, Nazran

Natalya S. Tsygankova

Smolensk Regional Oncological Clinical Dispensary

Email: krisman03@gmail.com

Oncologist

Russian Federation, Smolensk

Kseniya V. Chermakova

Ostroverkhov Kursk Cancer Research and Clinical Center

Email: krisman03@gmail.com

Oncologist

Russian Federation, Kursk

Tatyana A. Chirkova

Rappoport Novokuznetsk branch of the Kuzbass Clinical Oncological Dispensary

Email: krisman03@gmail.com

Department Head

Russian Federation, Novokuznetsk

Igor V. Samoylenko

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0001-7150-5071

Cand. Sci. (Med.)

Russian Federation, Moscow

Valeria V. Nazarova

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0003-0532-6061

Cand. Sci. (Med.)

Russian Federation, Moscow

Angelina E. Akhmetyanova

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com

Graduate Student

Russian Federation, Moscow

Lev V. Demidov

Blokhin National Medical Research Center of Oncology

Email: krisman03@gmail.com
ORCID iD: 0000-0002-8562-6082

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi: 10.3322/caac.21590
  2. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708
  3. Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33-44. doi: 10.1016/j.ejca.2019.11.016
  4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-46. doi: 10.1056/NEJMoa1910836
  5. Строяковский Д.Л., Абдулоева Н.Х., Демидов Л.В., и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12:287-306 [Stroiakovskii DL, Abduloyeva NKh, Demidov LV, et al. Prakticheskiie rekomendatsii po lekarstvennomu lecheniiu melanomy kozhi. Zlokachestvennyie opukholi: Prakticheskiie rekomendatsii RUSSCO #3s2. 2022;12:287-306 (in Russian)]. doi: 10.18027/2224-5057-2022-12-3s2-287-306
  6. Строяковский Д.Л., Абрамов М.Е., Демидов Л.В., и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли. 2020;10(3s2-1):267-82 [Stroyakovskii DL, Abramov MIe, Demidov LV, et al. Prakticheskiie rekomendatsii po lekarstvennomu lecheniiu melanomy kozhi. Zlokachestvennyie opukholi. 2020;10(3s2-1):267-82 (in Russian)]. doi: 10.18027/2224-5057-2020-10-3s2-16
  7. Безопасность лекарственных препаратов. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9ff3bf8-ba51-49d5-b345-a0358758ca46. Ссылка активна на 11.11.2022 [Drug Safety. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9ff3bf8-ba51-49d5-b345-a0358758ca46. Accessed: 11.11.2022 (in Russian)].
  8. Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030
  9. Donia M, Kimper-Karl ML, Høyer KL, et al. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer. 2017;74:89-95. doi: 10.1016/j.ejca.2016.12.017
  10. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466
  11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26. doi: 10.1056/NEJMoa1104621
  12. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082
  13. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-32. DOI:NEJMoa1503093
  14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or mono- therapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. doi: 10.1056/NEJMoa1504030
  15. Real-World Evidence. Available at: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence. Accessed: 11.11.2022.
  16. Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice (FORA). Available at: https://clinicaltrials.gov/ct2/show/NCT05120024?term=prolgolimab&draw=2&rank=1. Accessed: 11.11.2022.
  17. Kuzmanovszki D, Kiss N, Toth B, et al. Anti-PD-1 Monotherapy in Advanced Melanoma-Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines. 2022;10(7):1737. doi: 10.3390/biomedicines10071737
  18. Mohr P, Scherrer E, Assaf C, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers. 2022;14(7):1804. doi: 10.3390/cancers14071804
  19. Monestier S, Dalle S, Mortier L, et al .Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. Int J Cancer. 2021;148(11):2789-98. doi: 10.1002/ijc.33467
  20. Frank GA, Aleksakhina SN, Zavalishina LE, et al. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Melanoma Res. 2016;26(5):442-7. doi: 10.1097/CMR.0000000000000278
  21. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-37. doi: 10.1200/JCO.21.02229

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies